SAN FRANCISCO—Okupe Oluyemi, Chief Financial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has recently reported the sale of company shares amounting to $283,083, according to a recent SEC filing. The transactions, executed on January 13, 2025, involved the sale of 11,581 shares of Class A Common Stock at prices ranging from $24.4151 to $24.5688.
Additionally, Oluyemi exercised stock options to acquire 6,437 shares at a price of $5.01 per share, as part of a pre-established trading plan under Rule 10b5-1. Following these transactions, Oluyemi now holds 118,077 shares directly. According to InvestingPro, the company maintains strong financial health with a GREAT overall score and expects continued net income growth this year.
These activities are part of a trading plan adopted on May 31, 2024, allowing for systematic buying and selling of shares. Hims & Hers Health, Inc. continues to focus on providing accessible healthcare solutions, with its leadership team actively managing their equity positions.
In other recent news, Hims & Hers Health has been the focus of significant developments. The company's revenue growth continues to impress, with a 77% year-over-year increase in Q3 sales, surpassing $400 million, and an adjusted EBITDA over $50 million. Revenue projections for Q4 2024 range between $465 million and $470 million, indicating a substantial year-over-year increase.
BTIG initiated coverage on Hims & Hers, assigning a Buy rating and expressing confidence in the company's innovative business model. Needham & Company also raised their price target on the company, positioning it as their top pick for 2025 due to its diverse growth avenues.
Morgan Stanley (NYSE:MS) initiated coverage on the company as well, assigning an Overweight rating and acknowledging its potential in the digital health and direct-to-consumer sectors. Meanwhile, the FDA's resolution of the tirzepatide injection shortage may alter market dynamics for obesity drugs, impacting Hims & Hers, which recently announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound.
These are among the recent developments that continue to shape the trajectory of Hims & Hers Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.